G57321FI
| Organisms | Evidence |
|---|---|
| Fasciola hepatica (liver fluke) | |
| Toxocara canis (dog roundworm) | |
| Echinococcus granulosus | |
| Oryctolagus cuniculus (rabbit) | |
| Ovis aries (sheep) |
| Gene Symbol | Donor | Acceptor | Reducing terminal(Acceptor) | Product | Reducing terminal(Product) | Reference |
|---|---|---|---|---|---|---|
| C1GALT1 | (not applicable) |
|
Ser/Thr |
|
Ser/Thr | |
| ST6GALNAC1 | CMP-Neu5Ac |
|
Ser/Thr |
|
Ser/Thr | |
| ST6GALNAC1 | CMP-Neu5Ac |
|
O-glycan Synthesis |
|
O-glycan Synthesis | |
| B3GNT6 | UDP-GlcNAc |
|
[alpha]-pNP |
|
[alpha]-pNP |
| Gene Symbol | Donor | Acceptor | Reducing terminal(Acceptor) | Product | Reducing terminal(Product) | Reference |
|---|---|---|---|---|---|---|
| C1GALT1 | (not applicable) |
|
Ser/Thr |
|
Ser/Thr | |
| ST6GALNAC4 | CMP-Neu5Ac |
|
benzyl |
|
benzyl | |
| ST6GALNAC1 | CMP-Neu5Ac |
|
Ser/Thr |
|
Ser/Thr | |
| ST6GALNAC1 | CMP-Neu5Ac |
|
O-glycan Synthesis |
|
O-glycan Synthesis | |
| ST6GALNAC1 | CMP-Neu5Ac |
|
[Ala-Thr(*)-Ala]2-7 |
|
[Ala-Thr(*)-Ala]2-7 |
| Gene Symbol | Donor | Acceptor | Reducing terminal(Acceptor) | Reference |
|---|---|---|---|---|
| ST6GALNAC2 | CMP-Neu5Ac |
|
para-nitrophenol | |
| ST6GALNAC1 | CMP-Neu5Ac |
|
[alpha]-Bz | |
| ST6GALNAC3 | CMP-Neu5Ac |
|
Ser/Thr | |
| ST6GALNAC2 | CMP-Neu5Ac |
|
Ser/Thr | |
| ST6GAL2 | CMP-Neu5Ac |
|
para-nitrophenol |
| Pathway Name | Organism |
|---|---|
| E.coli O101 | Escherichia coli |
| E.coli O103 | Escherichia coli |
| E.coli O107 | Escherichia coli |
| E.coli O112ab | Escherichia coli |
| E.coli O112ac | Escherichia coli |
| E.coli O116 | Escherichia coli |
| E.coli O117 | Escherichia coli |
| E.coli O125ab | Escherichia coli |
| E.coli O127 | Escherichia coli |
| E.coli O128ab-H27 | Escherichia coli |
| PubMed ID | Title | First Author | Publication Date | Source |
|---|---|---|---|---|
| 28087069 | Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial | van der Ree MH | 2017 Feb 18 |
|
| 28158620 | Characterizing the effect of GalNAc and phosphorothioate backbone on binding of antisense oligonucleotides to the asialoglycoprotein receptor | Schmidt K | 2017 Feb 03 |
|
| 27984144 | Lectin from seeds of a Brazilian lima bean variety (Phaseolus lunatus L. var. cascavel) presents antioxidant, antitumour and gastroprotective activities | e Lacerda RR | 2017 Feb |
|
| 27973758 | Structural analysis and unique molecular recognition properties of a Bauhinia forficata lectin that inhibits cancer cell growth | Lubkowski J | 2017 Feb |
|
| 29046357 | Structural and thermodynamic analyses reveal critical features of glycopeptide recognition by the human PILRα immune cell receptor | Furukawa A | 2017 Dec 22 |
|
| 29166012 | The Use of Fluoroproline in MUC1 Antigen Enables Efficient Detection of Antibodies in Patients with Prostate Cancer | Somovilla VJ | 2017 Dec 12 |
|
| 29208955 | The interdomain flexible linker of the polypeptide GalNAc transferases dictates their long-range glycosylation preferences | de las Rivas M | 2017 Dec 05 |
|
| 29193962 | Cell Penetrating Polymers Containing Guanidinium Trigger Apoptosis in Human Hepatocellular Carcinoma Cells unless Conjugated to a Targeting N-Acetyl-Galactosamine Block | Tan Z | 2017 Dec 01 |
|
| 28526733 | Discovery and Optimization of HKT288, a Cadherin-6–Targeting ADC for the Treatment of Ovarian and Renal Cancers | Bialucha CU | 2017 Aug 31 |
|
| 28809818 | Synthesis of 5′-GalNAc-Conjugated Oligonucleotides: A Comparison of Solid and Solution-Phase Conjugation Strategies | Cedillo I | 2017 Aug 15 |
|
GlyCosmos is a member of the GlySpace Alliance together with GlyGen and Glycomics@ExPASy.
Supported by JST NBDC Grant Number JPMJND2204
Partly supported by NIH Common Fund Grant #1U01GM125267-01
This work is licensed under Creative Commons Attribution 4.0 International
GlyCosmos Portal v4.4.0
Last updated: December 8, 2025